Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.63 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.58 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30288530 | 1.00 | HDAC3 (0.63) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29372818 | 1.00 | HDAC3 (0.63) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29781391 | 0.82 | P2RX1 (0.56) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL14582017 | 0.82 | P2RX1 (0.56) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL10607741 | 0.81 | P2RX1 (0.63) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL10347262 | 0.80 | P2RX1 (0.56) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL17134082 | 0.78 | HDAC3 (0.58) | HDAC3HDAC1HDAC2MAPTMEN1 | |
| Salfluverine SCHEMBL1552202 | 0.78 | P2RX1 (0.69) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL31129776 | 0.78 | HDAC3 (0.78) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL17817420 | 0.78 | HDAC3 (0.78) | HDAC3HDAC1HDAC2HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313026-A1 | ACTIVE DELIVERY SYSTEM FORMULATIONS | Castle Beach, L.L.C. (US) | 2011-04-27 | — | — | EP | claimed |
| EP-2209472-A1 | USE OF NITRIC OXIDE TO ENHANCE THE EFFICACY OF SILVER AND OTHER TOPICAL WOUND CARE AGENTS | The University of North Carolina at Chapel Hill (US) | 2010-07-28 | — | — | EP | claimed |
| US-20100040565-A1 | ACTIVE DELIVERY SYSTEMS FORMULATIONS | Castle Beach, LLC (US) | 2010-02-18 | — | — | US | claimed |
| WO-2010019680-A1 | ACTIVE DELIVERY SYSTEM FORMULATIONS | HOMOLA ANDREW M (US) | 2010-02-18 | — | — | WO | claimed |
| WO-2009049208-A1 | USE OF NITRIC OXIDE TO ENHANCE THE EFFICACY OF SILVER AND OTHER TOPICAL WOUND CARE AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-04-16 | — | — | WO | claimed |
| EP-0805672-B1 | METHODS, COMPOSITIONS, AND DENTAL DELIVERY SYSTEMS FOR THE PROTECTION OF THE SURFACES OF TEETH | HOMOLA ANDREW M (US) | 2004-08-25 | — | — | EP | claimed |
| US-5665333-A | Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth | PROVSEAL LLC | 1997-09-09 | — | — | US | claimed |
| EP-0628302-A2 | Oral composition containing salicylanilide antibacterial agent | Colgate-Palmolive Company (US) | 1994-12-14 | — | — | EP | claimed |
| US-5275805-A | Inhibitors of plaque in mouths with mixtures of salicylanilide and nonionic surfactants | COLGATE-PALMOLIVE CO. | 1994-01-04 | — | — | US | claimed |
| EP-3528776-B1 | REDUCED-ETHANOL MOUTH RINSE FORMULATIONS | KENVUE BRANDS LLC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4088716-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024008261-A1 | CANNABINOID LIPID PREMIXTURE | FERTIN PHARMA A/S (DK) | 2024-01-11 | — | — | WO | disclosed |
| US-11857653-B2 | Method of providing an oral care benefit using a poorly-soluble calcium compound and fluoride | JOHNSON & JOHNSON CONSUMER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3787604-B1 | A TABLETED CHEWING GUM SUITABLE FOR ACTIVE PHARMACEUTICAL INGREDIENTS | FERTIN PHARMA AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| EP-0223515-A2 | Oral compositions comprising salicylamides and zinc salts for the synergistic inhibition of dental plaque | UNILEVER PLC (GB) | 1987-05-27 | — | — | EP | disclosed |
| US-4659826-A | Synthesis of salicylamides with improved yield and purity | LEVER BROTHERS COMPANY (US) | 1987-04-21 | — | — | US | disclosed |
| US-4656031-A | SURFACTANT, ABRASIVE AND ANTI-PLAQUE AGENT | LEVER BROTHERS COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0161898-A2 | Dentifrice compositions | UNILEVER PLC (GB) | 1985-11-21 | — | — | EP | disclosed |
| EP-0144204-A2 | Process for preparing salicylamide compounds | UNILEVER PLC (GB) | 1985-06-12 | — | — | EP | disclosed |
| EP-0143628-A2 | Process for preparing salicylamide compounds | UNILEVER PLC (GB) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040565-A1 | ACTIVE DELIVERY SYSTEMS FORMULATIONS | LIPA, MMP7, CTSA | HDAC3 1596/4885HDAC1 1347/4885HDAC2 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.